CN106413701A - 用于治疗中性粒细胞减少症的组合物和方法 - Google Patents

用于治疗中性粒细胞减少症的组合物和方法 Download PDF

Info

Publication number
CN106413701A
CN106413701A CN201580009151.6A CN201580009151A CN106413701A CN 106413701 A CN106413701 A CN 106413701A CN 201580009151 A CN201580009151 A CN 201580009151A CN 106413701 A CN106413701 A CN 106413701A
Authority
CN
China
Prior art keywords
csf
illness
analog
retinoid agonist
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580009151.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Los Angeles
Original Assignee
Children's Hospital of Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Los Angeles filed Critical Children's Hospital of Los Angeles
Publication of CN106413701A publication Critical patent/CN106413701A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
CN201580009151.6A 2014-02-18 2015-02-18 用于治疗中性粒细胞减少症的组合物和方法 Pending CN106413701A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461941233P 2014-02-18 2014-02-18
US61/941,233 2014-02-18
PCT/US2015/016447 WO2015126989A1 (en) 2014-02-18 2015-02-18 Compositions and methods for treating neutropenia

Publications (1)

Publication Number Publication Date
CN106413701A true CN106413701A (zh) 2017-02-15

Family

ID=53878925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580009151.6A Pending CN106413701A (zh) 2014-02-18 2015-02-18 用于治疗中性粒细胞减少症的组合物和方法

Country Status (11)

Country Link
US (1) US10286039B2 (cg-RX-API-DMAC10.html)
EP (1) EP3107533A4 (cg-RX-API-DMAC10.html)
JP (1) JP2017508737A (cg-RX-API-DMAC10.html)
KR (1) KR20160113302A (cg-RX-API-DMAC10.html)
CN (1) CN106413701A (cg-RX-API-DMAC10.html)
AU (1) AU2015219038B2 (cg-RX-API-DMAC10.html)
CA (1) CA2937340C (cg-RX-API-DMAC10.html)
MX (1) MX2016010699A (cg-RX-API-DMAC10.html)
RU (1) RU2016136833A (cg-RX-API-DMAC10.html)
WO (1) WO2015126989A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201605109B (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107130026A (zh) * 2017-05-15 2017-09-05 新疆医科大学第四附属医院 一种结直肠癌诊断和治疗效果评价相关的基因
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
CN112390731A (zh) * 2020-11-16 2021-02-23 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN111886008B (zh) * 2017-10-18 2024-05-31 港大科桥有限公司 用于抗mers-冠状病毒治疗的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816345A (zh) * 2003-05-16 2006-08-09 协和发酵工业株式会社 伴有组织破坏的疾病的预防剂和/或治疗剂
WO2013185105A1 (en) * 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2273288A1 (en) 1996-12-19 1998-06-25 James Joseph Gibbons Method of treating or inhibiting neutropenia
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003902308A0 (en) 2003-05-14 2003-05-29 Diagnose It Pty Ltd A method and system for the monitoring of medical conditions
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
RS51506B (sr) 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
WO2006071451A2 (en) 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
MX2009009997A (es) 2007-03-30 2009-12-08 Tmrc Co Ltd Preparacion de la capsula de tamibarotene.
JP2011505386A (ja) 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
US8580516B2 (en) * 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
US20160172942A1 (en) 2013-07-04 2016-06-16 Linak A/S Actuator system
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816345A (zh) * 2003-05-16 2006-08-09 协和发酵工业株式会社 伴有组织破坏的疾病的预防剂和/或治疗剂
WO2013185105A1 (en) * 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HISASHI TSURUMI等: "The combined effects of all-trans retinoic acid and granulocyte colony-stimulating factor as a differentiation induction therapy for acute promyelocytic leukemia.", 《INTERNAL MEDICINE》 *
丁婉婧: "维甲酸受体激动剂AM80诱导造血肝细胞分化形成的中性粒细胞的杀菌功能及机制研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
CN107130026A (zh) * 2017-05-15 2017-09-05 新疆医科大学第四附属医院 一种结直肠癌诊断和治疗效果评价相关的基因
CN112390731A (zh) * 2020-11-16 2021-02-23 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
AU2015219038A1 (en) 2016-08-04
KR20160113302A (ko) 2016-09-28
EP3107533A4 (en) 2017-10-18
EP3107533A1 (en) 2016-12-28
ZA201605109B (en) 2017-09-27
CA2937340C (en) 2022-06-14
US20170007672A1 (en) 2017-01-12
AU2015219038B2 (en) 2018-10-18
US10286039B2 (en) 2019-05-14
JP2017508737A (ja) 2017-03-30
RU2016136833A3 (cg-RX-API-DMAC10.html) 2018-10-19
RU2016136833A (ru) 2018-03-22
WO2015126989A1 (en) 2015-08-27
CA2937340A1 (en) 2015-08-27
MX2016010699A (es) 2017-10-11

Similar Documents

Publication Publication Date Title
JP7328187B2 (ja) がん及び感染症の治療方法並びに治療用組成物
US12496345B2 (en) Method of treating cancer
UA129329C2 (uk) ЗЛИТІ БІЛКИ FLT3L-Fc
US11116738B2 (en) Methods for treating neutropenia using retinoid agonists
CA2937340C (en) Compositions and methods for treating neutropenia
ES2643321T3 (es) Una combinación de un antagonista de CXCR4 y citarabina para su uso en el tratamiento de la leucemia mieloide
US11427617B2 (en) Compositions and methods for treatment of fungal infections
US12012440B2 (en) Compositions and methods for treatment of fungal infections
JPWO2005046715A1 (ja) 生理活性複合体
WO2013134666A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170215